UPDATE: Tevogen Bio Forecasts $1B Launch-Year Revenue, Sees $18B–$22B Over 5 Years, Driven By PASC Treatment And Oncology Pipeline

Author: Benzinga Newsdesk | August 11, 2025 01:30pm

• Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.
• Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

Posted In: TVGN